1 153

Cited 11 times in

Rebamipide affects the efficiency of colchicine for the herpes simplex virus-induced inflammation in a Behcet's disease mouse model.

Authors
 Dongsik Bang  ;  Bunsoon Choi  ;  Hyuk Jae Kwon  ;  Eun-So Lee  ;  Sungnack Lee  ;  Seonghyang Sohn 
Citation
 EUROPEAN JOURNAL OF PHARMACOLOGY, Vol.598(1-3) : 112-117, 2008 
Journal Title
 EUROPEAN JOURNAL OF PHARMACOLOGY 
ISSN
 0014-2999 
Issue Date
2008
MeSH
Alanine/analogs & derivatives* ; Alanine/pharmacology ; Animals ; Anti-Inflammatory Agents, Non-Steroidal* ; Behcet Syndrome/drug therapy* ; Behcet Syndrome/pathology ; Colchicine/therapeutic use* ; Enzyme-Linked Immunosorbent Assay ; Herpes Simplex/drug therapy* ; Herpes Simplex/pathology ; Inflammation/drug therapy* ; Inflammation/pathology ; Male ; Mice ; Mice, Inbred ICR ; NADPH Oxidases/metabolism ; Quinolones/pharmacology* ; RNA, Messenger/biosynthesis ; RNA, Messenger/genetics ; Reverse Transcriptase Polymerase Chain Reaction ; Tubulin Modulators/therapeutic use*
Keywords
Rebamipide ; Behcet's disease ; Herpes simplex virus ; Mouse model ; NADPH oxidase
Abstract
Rebamipide inhibits free radicals derived from activated neutrophils and decreases the inhibiting inflammatory cytokine. Behcet's disease (BD) is a chronic, multi-systemic inflammatory disorder with arthritic, gastrointestinal, mucocutaneous, ocular, vascular, and central nervous system involvement. This disease has a chronic course with periodic exacerbations and progressive deterioration. To study the effect of rebamipide treatment to BD-like mice, combination treatment with rebamipide and colchicine was compared to colchicine treatment. Colchicine is one of the most frequently prescribed medicine to the patients with BD. For each BD mouse, 200 microl gastric fluid or 2 microg colchicine or 150 microg rebamipide or 2 microg colchicine plus 150 microg rebamipide was treated orally once per day. Treatment was done for 5 consecutive days. Two hour or 20 days after last administration, spleens were isolated for RT-PCR and real time PCR, and serum was collected for ELISA. In the combination treated group, TNF alpha, MIP-1 alpha, p22 phox, p47 phox, and gp91 phox mRNA expressions were lower than rebamipide treated or colchicine treated groups by reverse transcriptase PCR. NADPH oxidase subunits mRNA were markedly downregulated compared to the colchicine treated group by real time PCR. At 20 days after administration, combination treatment decreased 23.5% of the severity score compared to before administration. In contrast, colchicine treatment decreased 14.3% of the severity score compared to before administration. Rebamipide helped the function of colchicine to improve the HSV induced BD-like symptoms by inhibiting the expression of NADPH oxidase in vivo mouse model.
Full Text
http://www.sciencedirect.com/science/article/pii/S0014299908009424
DOI
10.1016/j.ejphar.2008.09.005
Appears in Collections:
1. College of Medicine (의과대학) > Dept. of Dermatology (피부과학교실) > 1. Journal Papers
Yonsei Authors
Bang, Dong Sik(방동식)
URI
https://ir.ymlib.yonsei.ac.kr/handle/22282913/108604
사서에게 알리기
  feedback

qrcode

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.

Browse